DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $452.16M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.29M
Average 0.19M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Denali Therapeutics Inc. NASDAQ:DNLI | $3.00B | $18.74 | Not rated | -8.7 | +2.97% |
Maze Therapeutics, Inc. NASDAQ:MAZE | $1.88B | $34.33 | Not rated | -11.0 | -1.08% |
BioAge Labs, Inc. NASDAQ:BIOA | $208.96M | $5.55 | Not rated | -9.7 | -38.18% |
ProKidney Corp. NASDAQ:PROK | $154.83M | $1.05 | Not rated | -3.3 | -51.75% |
Akebia Therapeutics, Inc. NASDAQ:AKBA | $131.67M | $0.47 | Undervalued | -13.3 | -75.73% |
Unicycive Therapeutics, Inc. NASDAQ:UNCY | $97.25M | $3.55 | Not rated | -40.8 | -37.50% |
Continue the stock analysis
Jump to another research area for this company.